The overview discusses fifty eight peptides in different clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. More than 200 ncAAs with numerous functionalities have already been genetically encoded into different organisms up to now, for instance Escherichia coli The rising incorporation of peptides in anti-agi